Tissue Engineered Skin Substitutes Market Analysis and In-depth Research on Size, Trends, Emerging Growth Factors and Forecasts 2023

The top four players in the global tissue engineered skin substitutes market hold almost 60.0% share in it. As a result the competitive landscape is somewhat consolidated. In 2014, Acelity accounted for a leading share of 21.5% in the market on account of a wide array of products that are much in demand. Smith & Nephew followed in the second position with its solid distribution and marketing strategies, targeting particularly the developing economies in Eastern Europe, Latin America, the Middle East, and Asia Pacific. The third and fourth positions in the market was occupied by Molnlycke and ConVatec.
This 67 page report gives readers a comprehensive overview of the tissue engineered skin substitutes market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/tissue-engineered-skin-substitute.html
The competition in the global market for tissue engineered skin substitutes is stiff with most well-entrenched players investing heavily in research and development to bring about product differentiation which improves their marketability. The leading players are also resorting to mergers and acquisitions to gain a foothold in the local markets. As far as new entrants in the market are concerned, stringent regulatory policies pertaining to manufacture and commercialization of products has created a barrier for them.
The global market for tissue engineered skin substitutes is predicted to expand at a robust CAGR of 17.2% from 2015 to 2023 to rake in an estimated revenue of US$3.87 bn by 2023 from US$1.2 bn in 2016.
Burgeoning Population to Drive Phenomenal Growth in Asia Pacific Market
Depending upon the type of device, acellular skin substitutes leads with over half of the market share. Going forward too, their market is slated to expand at a cracking pace due to their strong demand, especially in implant-based skin surgery. Their relatively lower cost and easy availability are other factors pushing their demand in the market. Revenue-wise, the acellular skin substitutes market was worth US$6.192 bn in 2015.
Geographically, the Asia Pacific market is slated to grow at a scorching pace in the upcoming years due to a burgeoning population and a fast improving healthcare infrastructure. However, in terms of market share, North America leads with maximum – about half – share. In the future too, it is expected to hold on to its dominant share to attain a value of US$1.967 vis-à-vis revenue.
Rising Geriatric Population at the Forefront of Stoking Demand
A burgeoning geriatric population, highly prone to skin diseases like vascular ulcers and having lowered immunity and blood flow, has majorly contributed to the global market for tissue engineered skin substitutes. Another major growth driver in the market is the increasing prevalence of vascular diseases and disorders such as vascular ulcers, DVT, etc. “As per the Center for Disease Control and Prevention, about 900, 000 people are afflicted by DVT annually. DVT also claims about 60, 000 and 100, 000 lives in the U.S. each year. Most people suffering from vascular disease undergo skin surgeries. Hence, a consistent rise in vascular diseases is likely to boost demand for tissue engineered skin substitutes,” states the analyst of the TMR report.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving tissue engineered skin substitutes market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3854
Competitive Pricing of Local Players to Hamper Market Growth
Countering the growth in the global market for tissue engineered skin substitutes is the competitive pricing strategies by local players. This has intensified competition and put a downward pressure on prices. In the near future, this would likely deal a blow to the healthy growth in the market. Additionally, continued technological progress vis-à-vis product design and efficiency may not bode well for the market owing to the reluctance on the part of consumers to upgrade to expensive advanced procedures and products. The trend would be particularly noticeable in the emerging economies of Brazil, China, and Mexico, where people do not have very high purchasing power.
This review is based on the findings of a TMR report titled “Tissue Engineered Skin Substitutes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.

Multi-parameter Patient Monitoring Equipment Market: Business Challenges, Emerging Technologies & Competitive Landscape

The global multi-parameter patient monitoring equipment market is expected to reach US$4.6 bn by 2023. It was recorded at US$3.1 bn in 2014 and is exhibiting a CAGR of 4.4% between 2015 and 2023, according to a research report released by Transparency Market Research. The report is titled “Multi-parameter Patient Monitoring Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023” and is available on the company website for sale.
According to the report, the global multi-parameter patient monitoring equipment market is primarily driven by the large and increasing number of patients suffering from chronic diseases. Other major drivers include the positive rate of developments occurring in this market, such as the incorporation and enhancement of home monitoring and remote monitoring.
This 91 page report gives readers a comprehensive overview of the multi-parameter patient monitoring equipment market. Browse through 9 data tables and 30 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/multi-parameter-patient-monitoring-equipment.html
A major restraint acting on the global multi-parameter patient monitoring equipment market is the numerous recent product recalls. Each product recall has increased the sense of brand confusion among consumers and has led to the discrediting of certain major companies. The growth rate of the global market, however, can still be maintained through increased penetration in developing economies across the world.
The report provides a detailed analysis of the global multi-parameter patient monitoring equipment market by segmenting it on the basis of acuity level, end use, and geography.
In terms of acuity levels, the report explains that nearly 40.0% of the market was occupied by high-acuity monitors in 2014. This segment dominated the market due to the high demand for them in ICUs. The report, however, states that low-acuity monitors will display the fastest growth rate in the given forecast period.
In terms of end users, the global multi-parameter patient monitoring equipment market is led by the hospitals segment. This segment topped the market in 2014 due to the high number of patients that were critically ill and required monitoring. Throughout the forecast period, the segment of home monitoring is expected to grow at the fastest rate owing to the increasing geriatric population, along with improvements in technology.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving multi-parameter patient monitoring equipment market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1692
The report’s regional analysis shows Asia Pacific to possess the fastest growth rate in the market. The Asia Pacific multi-parameter patient monitoring equipment market is growing at a rapid rate due to the region’s high population density, the growing number of individuals with high disposable income, and the growing number of cases of chronic disorders in the countries of China and India, most particularly in the respiratory and cardiovascular fields.
North America dominated the global multi-parameter patient monitoring equipment market in 2014, owing to the region’s highly advanced healthcare infrastructure and active government investments.
The key players in the global multi-parameter patient monitoring equipment market are Schiller AG, Guangdong Biolight Meditech Co. Ltd., CAS Medical Systems Inc., Nihon Kohden Corporation, Philips Healthcare, GE Healthcare, Mindray Medical International Limited, and Spacelabs Healthcare.

Organ Transplant Immunosuppressant Drugs Market: Emerging Market Trends, Size, Share and Growth Analysis

The global organ transplant immunosuppressant drugs market is fairly consolidated, with the top 5 vendors contributing over 90% of the market in 2014. Transparency Market Research (TMR) notes that these leading companies–Novartis AG, Astellas Pharma, Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., and Sanofi–are offering a robust and diverse product portfolio, including blockbuster drugs, to consolidate their market shares. They are updating their pipelines after the impending patient expiry of blockbuster drugs.
The increasing incidence rate of various life-threatening ailments has stimulated the demand for organ replacement therapies and transplants as the last line of treatment to treat organ failures or disabilities. This is a key driver fuelling the growth of the market. According to the TMR’s estimation, the global organ transplant immunosuppressant market was valued at US$5.1 bn in 2014. The market is anticipated to register a CAGR of -5.0% between 2015 and 2023 with the market’s valuation estimated to reach US$3.2 bn by 2023.
This 102 page report gives readers a comprehensive overview of the organ transplant immunosuppressant drugs market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/organ-transplant-immunosuppressant-drugs.html
Immunosuppressant Drugs for Successful Kidney Transplantation Propel Market Growth
Over the last couple of years, kidney transplantation has emerged as the preferred treatment method for end-stage kidney disorder, as the replacement proves to be more cost-effective than dialysis. The use of immunosuppressant drugs has been considered as a vital element for the long-term success of kidney transplants. According to findings by TMR, the segment occupied over 53.4% of the market in 2014 and is expected to lead the market through 2023. Rising incidence rate of kidney disorders is expected to fuel the growth of this segment. Furthermore, the rising incidence other of chronic ailments, which may need liver, heart, and lung transplants, mainly among geriatric population, is expected to spur the demand for organ transplant immunosuppressant drugs.
In addition, the emerging demand for bone marrow transplant has expedited the discovery of novel immunosuppressant drugs and therapies. Recent developments suggest that immunosuppression is found to offer promising line of treatment for the management of graft-versus-host diseases.
High Cost of Organ Replacement Surgeries may Act as Restraint
The high cost of organ transplant procedures, significant shortage of donors, and the considerable expenditure required for the care of patients post-transplantation are likely to restrain the growth of the market in some regions. Combined with them, the non-adherence of the immunosuppression therapies after transplantation owing to the lack of awareness among patients is another key restraining factor. Additionally, uncertainty of benefits of the use of immunosuppression for complex transplantation procedures, especially evident in case of liver transplantation, has impeded the market growth. In addition, the advent of stem cell therapies as a potential substitute for organ transplantation may restrict the growth of the global organ transplant immunosuppressant drugs market.
However, extensive clinical studies and R&D activities undertaken to develop and test novel immunosuppressant therapeutics is a key trend that will help minimize the cases of organ rejection for a number of transplantations, unlocking promising growth opportunities for the market players.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving organ transplant immunosuppressant drugs market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1967
Robust Healthcare Infrastructure to Spur Demand for Organ Transplant Immunosuppressant Drugs in North America
Regionally, North America is a prominent market for organ transplant immunosuppressant drugs. The growth is driven by the increasing rate of successful organ replacement surgeries and substantial investments from the government and private players to develop a robust healthcare infrastructure.
Europe is another region exhibiting tremendous potential for growth in the organ transplant immunosuppressant drugs market. Continuous advancements in surgical procedures for organ transplantation and innovations in immunosuppressant drug discovery are the crucial factors propelling the market growth in the region.
The study presented here is based on a report by Transparency Market Research (TMR) titled “Organ Transplant Immunosuppressant Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”

Patient Engagement Solutions Market - Latest Trends & Insights 2023

The leading players operating in the global patient engagement solutions market are Cerner Corporation, Mckesson Corporation, and Allscipts Healthcare Solutions, Inc., among others, as per Transparency Market Research (TMR). These players are adopting numerous competitive strategies in order to hold a better position in the market. Key players are integrating state-of-the-art and new features into their patient engagement solutions for making these systems more beneficial in enhancing the health of patients.
This 104 page report gives readers a comprehensive overview of the patient engagement solutions market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/patient-engagement-solutions-market.html
The global patient engagement solutions market stood at US$6.66 bn in 2014 and is poised to touch US$34.94bn in 2023, rising at a whopping 23.0% CAGR between 2015 and 2023. On the basis of delivery mode, the market is dominated by the segment of self-hosted delivery mode and this segment represented a share of 43.6% in 2014. It is also predicted to lead the market in forthcoming years. This is due to the extensive employment of patient engagement portals by big hospitals globally. On the other hand, the segment of Software as a Service delivery mode is poised to experience the swiftest development during the forecast horizon due to the high adoption of cloud-based services globally.
Patient Engagement Solutions Experience Huge Deployment in Pharmaceutical Companies
In terms of end user, the segment of pharmaceutical companies will maintain a lead position in the market and will rise at the most exponential CAGR. The global patient engagement solutions market by pharmaceutical companies is anticipated to touch US$7.64 bn by 2023, expanding at a remarkable 24.1% between 2015 and 2023. This is due to the fact that patient engagement solutions help pharmaceutical companies in capturing data and tracking of responses from the consumed medicines of patients. This helps the pharmaceutical companies in redeveloping and innovating their development strategies and medicines accordingly.
In terms of geography, the North America patient engagement solution market is poised to experience the most rapid growth. This is due to the increasing support provided through government reforms and the rising demand for good quality healthcare services within this region. In North America, the U.S. held the most dominant share of 70.9% in 2014 and the U.S. patient engagement solutions market is predicted to reach a value of US$8.53 bn by 2023, rising at an extraordinary 20.20% CAGR between 2015 and 2023.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving patient engagement solutions market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4506
Absence of IT Expertise may Restrain Growth of Patient Engagement Solutions Market
The global patient engagement solutions market is predicted to grow due to favorable reforms by governments in healthcare management services’ field, states a TMR analyst. In addition, the ease of access is also enabling numerous users to implement patient engagement solutions. On the other hand, factors such as absence of IT expertise may inhibit the development of the global patient engagement solutions market. “Lack of expertise is a key concern in emerging nations”, says a TMR analyst. The dearth of technological inputs and fragile technological base have also emerged as key factors that may inhibit the market for patient engagement solutions in emerging nations.
In addition, cloud computing features storing of data which is then processed at a third-party data center. The companies that prefer storing their data on public cloud, lack the physical means of accessing it. This may introduce a threat for that particular company and its clients. Hence, the maintenance of data security and privacy has also emerged as a key roadblock in the development of the global patient engagement solutions market.
This information is based on the findings of a report published by Transparency Market Research titled, “Patient Engagement Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”

Pain Management Devices Market: Impact of Key Factors Influencing the Parent Industry

With billions of people suffering from chronic pain worldwide, the condition not only stresses healthcare budgets but also leads to lost productive time every year. The need to provide timely and effective treatment for pain will fuel the global pain management market until 2023, says Transparency Market Research in a latest report. According to the report, the Pain Management Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 will post a compounded annual growth rate of 7.6% between 2015 and 2023 as it grows in size from US$3.2 bn in 2014 to US$6.3 bn by the end of 2023.
As more people worldwide enter the 65+ years age band, makers of pain management devices will find new growth avenues in this demographic space. At the same time, many new pain management devices are being commercialized and are thus contributing palpably to the overall revenue of the global pain management devices market.
This 102 page report gives readers a comprehensive overview of the pain management devices market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/pain-management-drugs-devices.html
The market will, however, not be devoid of challenges. For instance, a few reported risks associated with neurostimulation implant procedures have created a negative perception about their safety. This could hinder the growth of the global pain management devices market. Moreover, the implementation of the Affordable Care Act in the United States has eroded the profit margins of some key commercial entities in the global pain management devices market.
For a closer analysis of the various dynamics at play in the global pain management devices market, the report segments the market based on product type, application, and region.
Basis product type, the market has been segmented into electrical stimulation devices, analgesic infusion pumps, radiofrequency ablation devices, and neurostimulation devices. Some of these segments have been sub-segmented to the third level. The report states that in 2014, neurostimulation devices stood as the most dominant segment in the market. Their dominance is attributable to an increase in SCS and DBS device implantations among patients reporting pain in the trunk or limbs. The next few years will be especially profitable for the vagus nerve stimulation (VNS) devices. This segment will report an 8% CAGR over the review period of the report.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving pain management devices market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1143
Each of the key product types have been further studied on the basis of their specific applications. The key application areas studied are: Cancer-related pain, neuropathic pain, trauma, musculoskeletal pain, and migraine and facial pain. The use of pain management devices for treating neuropathic and musculoskeletal pain was the highest as compared to the other types of applications. The use of electrical stimulation devices for treating musculoskeletal pain, for instance, is expected to show healthy growth. TMR analysts project the sub-segment of musculoskeletal pain of the electrical stimulation devices applications segment to exhibit a 7% through the review period.



From the regional standpoint, the global pain management devices market has been split into: North America (Canada and the U.S.), Europe (U.K., Germany, and Rest of Europe), Latin America (Brazil and Rest of Latin America), Asia Pacific (Australia, China, Japan, and Rest of Asia Pacific), and Rest of the World. While the North America region exhibited the largest market for pain management devices, the highest and fastest growth will be shown by the Asia Pacific region until 2023.

ePharmacy Market is Expected to Rise at a Remarkable CAGR During 2015-2023

The global ePharmacy market is characterized by stiff competition. Transparency Market Research finds while, on one hand there are well-entrenched players, namely CVS Caremark and Walgreen Co., on the other hand there are ambitious new entrants, namely Rowlands Pharmacy and DocMorris NV Ltd. Companies such as Lloyds Pharmacy and eDrugstore.MD are amongst the promising ones registering relatively median growth, in comparison to market leaders. Medisave and Dr. Fox Pharmacy are companies, who have been pegged as niche players, are predicted to hold significant market share over the forecast period.
The market position of key vendors is determined using parameters such as geographic presence, product portfolio/service offerings, duration of activity in the market, and their recent key developments. CVS Caremark has overtaken all other companies on various parameters, to emerge as the dominant player in the ePharmacy market. It has witnessed decent growth in the past few years, which can be attributed to improved healthcare services and new, innovative products. Moreover, the company is concentrating more on developing its product line for pharmaceutical and beauty products.
This 58 page report gives readers a comprehensive overview of the ePharmacy market. Browse through 07 data tables and 12 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/epharmacies-market.html
The global market for ePharmacies stood at US$29.35 bn in 2014. It is forecasted to expand at an impressive CAGR of 17.7% during the forecast period from 2015 to 2023.
North America to Remain Dominant Market
Electronic pharmacy or internet pharmacy, popularly known as ePharmacy, enables the online retailing of medicines. Given the convenience it accords on account of round-the-clock purchase and delivery, useful information on prescribed drugs, and transparency in prices, among others, its popularity is growing by the day. The ePharmacy market, however, is yet to reach its full potential, with framework on ethical practices and governing policies on treatment and safe delivery of prescription drugs, still not built properly.
On the basis of geography, the ePharmacy market is segmented into: North America, Europe, Asia Pacific, Middle East and Africa (MEA), and Latin America. Healthcare delivery has evolved rapidly in North America in the past decade. North America currently leads the ePharmacy market owing to the high internet penetration and increasing number of takers for online prescription and delivery of medicines. The region is predicted to remain in a dominant position, in terms of revenue generation, in the forecast period. ePharmacy, on the flip side, has also led to substance abuse brought about by emergence of rogue online pharmacies. Taking cognizance of the situation, the authorities have implemented stringent regulations in the market. This has stifled market growth to some extent. The market for ePharmacies in North America was US$10.80 bn and it is expected to register a CAGR of 16.9% during the forecast period from 2015 to 2023 to reach US$44.93 bn in 2023. Europe, whose market is a bit wobbly currently, is expected to overtake North America by 2023, on account of better healthcare infrastructure and growing trend of online drugs ordering.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving ePharmacy market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=397
Increased Internet Penetration Leading to Increased Takers for Online Pharmacy
ePharmacies have been around for quite a while now in North America and Europe and are fast gaining traction in Asia Pacific too. Factors pushing growth in the ePharmacy market are increasing internet penetration both developed and developing economies, rising elderly population, and tech savvy consumers increasingly warming up to the idea of online shopping. “Purchase of prescription drugs through ePharmacies/online pharmacies would eliminate the excess cost incurred in the distribution of drugs from manufacturer to end consumer by eliminating the long distribution channel. Additionally, comprehensive information about the drugs at the consumer’s fingertips and round-the-clock delivery of drugs are some major reasons driving the shift toward the purchase of drugs through ePharmacies,” states the TMR analyst about growth drivers. He also states, “Deepening Internet penetration and easy availability of controlled prescription drugs such as stimulants, anxiolytics, narcotic painkillers, and sedative hypnotics through online retail platforms is indirectly resulting in increasing instances of substance abuse and has raised concerns for public health.” This, has resulted in stringent regulations in many regions, especially U.S., hampering market growth. Besides, the emergence of a large number of rogue pharmacies is also eroding consumers’ trust.
The information presented in this review is based on a Transparency Market Research report, titled, “ePharmacy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2015-2023.”

Cell Culture Market Outlook Key Analysis and Forecast by 2022

The global cell culture market is currently dominated by three major companies who together hold 52% of the market share. Thermo Fisher Scientific ranks on top with 32.9% of the market share, followed by BD Biosciences and EMD Millipore respectively. BD Biosciences has a strong presence in developed economies such as EU5 nations and U.S. Sigma-Aldrich is also a key player in the cell culture consumables business such as media, reagents, and sera. Corning Life Sciences offers economical platforms as compared to other companies. The report finds that high product differentiation plays a major role in determining the market position of the players. A large number of small players are entering the market too, especially in emerging economies, and the outsourcing of cell culture processes to cell culture companies has also increased the competition.
The global cell culture market was valued at US$6.0 bn in 2013 and is projected to reach US$11.3 bn by 2022, expanding at a CAGR of 7.1% during the forecast period.
This 127 page report gives readers a comprehensive overview of the cell culture market. Browse through 12 data tables and 49 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/cell-culture-market.html
Geographically, North America accounted for US$2.2 bn in 2013 and is expected to continue as the primary market for cell culture. Asia Pacific is projected to experience the strongest overall growth rate. By product type, consumables had the most significant demand valuation at US$3.4 bn in 2013 and the pattern is anticipated to continue.
Massive Investments Driving Cell Culture Market
Numerous sectors such as research, bioprocessing and manufacturing, academics, and regenerative medicines use cell culture, which has led to a growing demand for these products. As a result, leading pharmaceutical companies are now focusing on increasing their capabilities into biopharmaceutical manufacturing by entering into alliances with biotech companies. For instance, Thermo Fisher Scientific acquired Life Technologies in February 2014 to establish a stronghold over the cell culture market.
Massive capital investments and specificity of each bio-manufacturing process is leading to a shift toward contract manufacturing and research. Furthermore, the expanding scope of cell culture in areas such as stem cell research is also proving to be a positive influence on the market.
Artificial organs are engineered biological substitutes used to replace the structure and restore the functions of an impaired or diseased organ. The market for artificial organs is projected to expand at a double-digit CAGR during the forecast period. Moreover, the trend toward serum-free, specialty and customized media solutions is expected to boost market growth and the applicability of cell culture technology.
Demand for Advanced Manufacturing Capabilities to Fulfill Requirements
The process of cell culture is complex and requires monitoring several parameters such as temperature, humidity, nutrients, and toxins. Any deviation from the precise handling technique could have an impact on the efficacy of the end product. These constraints are expected to bottleneck the process of cell culture development and manufacturing.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving cell culture market during 2014 - 2022: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=405
Moreover, the growth of the cell culture market is also likely to be affected by the development of alternative technologies such as transgenic animals and plants for biopharmaceutical production. Ethical concerns over the use of animal sources is another aspect that may curtail the cell culture market growth.
“Cell culture model systems in drug discovery and drug evaluation is opening up significant possibilities for market growth and 3D cell culture is acting as a future opportunity in in vitro analysis too,” reveals the author of the report.
The information presented in this review is based on a Transparency Market Research report, titled, “Cell Culture Market : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022.”

Microfluidics Market: Reduced Costs to Ensure Swift Uptake of Microfluidics Technology

The global microfluidics market is highly consolidated with the dominant presence of three global players. The leading players — Danaher Corporation, F. Hoffman-La Roche AG, and Thermo Fisher Scientific — collectively accounted for a global market share of 53.0% in 2016, states Transparency Market Research (TMR). The top companies offer a diverse product portfolio. They are focusing on the expansion of their geographic presence to consolidate their market shares. Prominent players are launching innovative products for a wide spectrum of applications, including low-cost point-of-care testing, in medical diagnostics, drug discovery, and therapeutic devices.
This 213 page report gives readers a comprehensive overview of the microfluidics market. Browse through 29 data tables and 82 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/microfluidics-market.html
As per the TMR’s estimation, the global microfluidics market is anticipated to rise at a CAGR of 11.4% during the period 2016 – 2025. The global market for microfluidics was valued at US$ 4.76 bn in 2016 and is expected to attain a size of US$12.45 bn by 2025.
Advancement in Microfluidic Technologies to Stimulate Uptake
North America is expected to lead the global market and is forecast to acquire a share of 35.4% during 2017- 2025. Growth witnessed in this regional market is propelled by the advent of a range of advanced technologies related to point-of-care testing and the soaring demand for in-vitro diagnostics. Asia Pacific is expected to clock impressive growth in the microfluidics market through the forecast period. The introduction of portable and low cost microfluidic platforms in point-of-care testing in various developing countries of Asia Pacific is expected to unlock enormous opportunities for the market players to capitalize on.
Based on products, the global market is segmented into microfluidic chips, instruments, cartridges and reagents, and others. Among these, the cartridges and reagents segment is expected to dominate the market. The growth of the segment is fuelled by the wide applications of cartridges and reagents in assays and techniques due to enhanced accuracy, quick analysis, and economical reagent consumption which brings down the cost.
Advent of Low Cost Microfluidic Technologies in Point-of-Care Testing to Help Build Sales
Advancement in microfluidic platforms has significantly lowered the costs of diagnostic procedures, ensured lesser use of reagents, and enabled smaller size of medical devices. The demand for low-cost microfluidics in point-of-care diagnosis of various chronic diseases such as diabetes, cardiovascular ailments, and cancer has bolstered its demand in different developing regions, particularly across emerging markets of Asia Pacific. The rapidly growing geriatrics population who require fast and accurate diagnosis, coupled with continuous technological advances, in the areas of genomics and proteomics have spurred the demand for microfluidics across the globe. Several market players are using polymers in the manufacturing process of different microfluidic products which is expected to considerably reduce the manufacturing cost.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving microfluidics market during 2017 - 2025: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=18716
On the other hand, stringent approvals by global regulatory agencies, such as the U.S. FDA, for microfluidic devices and the high cost of instruments are likely to hinder the market growth to an extent. In addition, the limited reliability and packaging of these microfluidic devices is expected to adversely impact the market.
Nevertheless, dynamic collaborations between several global players and innovative methods of drug delivery are factors expected to impel the demand for microfluidic platforms and technologies.



The study presented here is based on a report by Transparency Market Research (TMR), titled “Microfluidics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025.

Label-free Array Systems Market Trends And Opportunities For The Industry By 2024

The global label-free array systems market is fairly consolidated, with the top five vendors accounting for a major share of 62.7% in the market in 2015. Transparency Market Research (TMR) notes that these leading companies – Biacore, Agilent Technologies, ForteBio, Molecular Devices LLC, and Perkin Elmer – are constantly offering unparalleled product portfolios and making technology innovations to gain a competitive edge over others. Timely upgrades and continuous product launches are the key strategies adopted by the leading companies to consolidate their market shares in various regions.
According to TMR’s estimation, the global label-free array systems market was valued at US$1.0 bn in 2015 and is anticipated to attain a valuation of US$1.7 bn by 2024. The global market is forecast to expand at a CAGR of 5.6% from 2016 to 2024.
This 132 page report gives readers a comprehensive overview of the label-free array systems market. Browse through 24 data tables and 48 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/label-free-array-systems-market.html
Robust R&D Spending in North America Lends Fillip to Market Growth
On the basis of geography, the global label-free array systems market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Of these, North America leads the global market. The regional market is estimated to occupy a major share in the coming years, and expected to register a CAGR of 5.7% during the forecast period. The regional market is primarily propelled by growing investments in research and development in the biotech and pharmaceutical sectors, accelerated adoptions of advanced technologies, and robust developments in drug discovery.
The primary end users of label-free array systems comprise research and development laboratories, contract research organizations (CROs), agriculture research institutes, and forensic institutes. Of these, research and development laboratories accounted for a major share in the global-label free array systems market in 2015. The increased spending on research and development by several biotechnology and pharmaceutical companies is a key trend that has fuelled the market growth. The demand for high-throughput equipment for discovering new molecules as promising drug candidates has boosted R&D spending in major regions, thus offering an impetus to the market.
Popularity of Outsourcing to Contract Research Organizations Creates Promising Market Avenues
The global label-free array systems market is expected to exhibit consistent growth fuelled by the demand for fast, accurate, and reliable results in molecular researches and in several drug discovery initiatives. Continuous advancement in technology has led to the design of high-throughput label-free array systems, which can offer real-time data analytics such as binding kinetics and affinity. In addition, the adoption of advanced label-free detection methods as plasmon sensing and nanowire sensing have enabled researchers the real-time monitoring of DNA amplification and finding novel biomarkers for cancer detection and treatment. Furthermore, unlike traditional labelled detection systems, the label-free array system ensures that the properties of the molecules under examination remain unaffected, thereby enhancing the accuracy of the results. All these factors are likely to open promising avenues in drug discovery and is expected to boost the market.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving label-free array systems market during 2016 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17225
Recent developments point to the rapid outsourcing of a major chunk of R&D activities to contract research organizations. A large number of pharmaceutical companies are partnering with leading CROs to outsource researches on drug development, which help them reduce production cost and meet quality standards. This will boost the uptake on new technologies.
The study presented here is based on a report by Transparency Market Research (TMR) titled “Label-free Array Systems Market (Technology - Surface Plasmon Resonance (SPR), Bio-layer Interferometry (BLI), Cellular Dielectric Spectroscopy (CDS), and Quartz Crystal Microbalance; End Users - R&D Laboratories, Contract Research Organizations, Agriculture Research Institutes, and Forensic Institutes; Applications - Drug Discovery, Antibody Characterization and Development, Protein Interface Analysis, and Protein Complex and Cascade Analysis) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Hematological Malignancies Market to 2024: Trends, Business Strategies and Opportunities with Key Players Analysis

The global hematological malignancies market is highly competitive in nature and is characterized by a consolidated nature, owing to the presence of a few players holding a large share of the overall market, states a research study by Transparency Market Research. The leading players operating in the global market, including Roche, Celgene, Novartis, and AbbVie are anticipated to remain dominant throughout the forecast period. In order to maintain their position and sustain in the competitive environment, the global market for hematological malignancies, these players are projected to focus on the expansion of the distributing on channels and network across the globe. In addition, the rising number of mergers and acquisitions are projected to benefit the market players in enhancing their presence across the globe. Furthermore, the emergence of new drugs and therapeutics for hematological malignancies is another major factor expected to accelerate the growth of the market in the near future.
According to the research study by Transparency Market Research, in 2015, the global market for hematological malignancies was worth US$27.4 bn. The market is estimated to register a healthy 7.50% CAGR between 2016 and 2024, reaching a value of US$51.9 bn by the end of 2024.
This 152 page report gives readers a comprehensive overview of the hematological malignancies market. Browse through 24 data tables and 60 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/hematological-malignancies-market.html
Availability of Advanced Therapeutics to Bolster North America Market
In the last few years, North America is anticipated to witness a strong growth throughout the forecast period. This region is likely to account for a lion’s share of the global market, owing to the increasing prevalence of hematological cancer. In addition, the easy availability of advanced therapeutics and the increasing awareness among consumers regarding hematological malignancies are anticipated to supplement the growth of the market in the next few years. Furthermore, Asia Pacific is likely to grow at a substantial pace throughout the forecast period. The Middle East and Africa and Latin America are projected to offer lucrative opportunities for key players operating in the hematological malignancies market across the globe.
On the basis of therapy, the global market for hematological malignancies has been categorized into targeted therapy, chemotherapy, and immunotherapy. In 2015, the immunotherapy segment led the global market, accounting for a major share. As per the research study, this segment is expected to remain in the leading position throughout the forecast period and register a healthy growth. The high preference of patients towards immunotherapy, due to its efficiency and low risks of side effects are predicted to supplement the growth of this segment in the next few years. Chemotherapy and targeted therapy segments are anticipated to witness a steady growth in the near future.
Increasing Lifestyle Disorders to Augment Global Hematological Malignancies Market
Request a sample of this report to know what opportunities will emerge in the rapidly evolving hematological malignancies market during 2016 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4580
A tremendous rise in the number of lifestyle-related disorders owing to the unhealthy and sedentary lifestyle of people across the globe is considered as the major factor anticipated to encourage the growth of the market of the market in the next few years. The rising number of cases of hematological malignances and the availability of effective therapeutics are anticipated to accelerate the growth of the global market in the forecast period. The development of the healthcare sector in several developing economies and the introduction of new drugs and treatments available in the global market are likely to contribute towards the market’s growth in the next few years.
However, the lack of favorable reimbursement policies and the high costs of drugs and therapeutics are anticipated to restrict the growth of the global hematological malignancies market over the forecast period. Nonetheless, the rising focus on research and development activities is predicted to generate promising and lucrative growth opportunities for the players operating in the global hematological malignancies market in the near future.
This information is based on the findings of a research report published by Transparency Market Research (TMR), titled “Hematological Malignancies Market (Disease Condition - Leukemia, Lymphoma, and Myeloma; Therapy - Chemotherapy, Immunotherapy, and Targeted Therapy; Distribution Channel - Hospital Pharmacies, Medical Stores, and E-commerce Platform) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Global Pulmonary Drugs Market Value Share Analysis, by Drug Class 2016 - 2024

The players in the global pulmonary drugs market are striving hard to concentrate on building their pipelines in a bid to develop effective medicines. Players are taking all the efforts to come up with medicines that give quick results. Meeting the unmet demands of the patient population across the globe is one of the areas on which players must focus so as to gain market shares and stay ahead in terms of competition level, finds Transparency Market Research (TMR) in its new research report on the pulmonary drugs market. The top five players in the industry are Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Astra Zeneca, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd. However as per the report, these players are likely to lose their shares in the market on account of patent expirations of various drugs in the years to come.
This 196 page report gives readers a comprehensive overview of the pulmonary drugs market. Browse through 36 data tables and 71 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/pulmonary-drugs-market.html
According to the research report, the global pulmonary drugs market is expected to rise from US$ 48,039.7 mn in 2015 to US$ 28,082.1 mn by 2024. The drop in the CAGR is likely to be -6.3% between 2016 and 2024. By drug class, the combination drugs segment is estimated to continue to lead in the market during the period from 2016 to 2024. On the basis of geography, Asia Pacific is most likely to be the lucrative regional segment contributing the most to the revenue of pulmonary drugs market. Asia Pacific is estimated to account for 23.1% of the global pulmonary drugs market between 2016 and 2024.
Rise in Asthma and COPD Incidences Continue to Drive Sales of Pulmonary Drugs
The global demand for pulmonary drugs is increasing as the number of patients suffering from chronic respiratory diseases is increasing steadily. As per the Forum of International Respiratory Societies (FIRS), around 200 mn deaths occur on account of chronic obstructive pulmonary disease (COPD). FIRS also stated that about 235 mn people are dying on account of asthma. The number of smokers across the globe has risen and this has resulted in the escalation of respiratory diseases among the people, fueling the demand for pulmonary drugs.
As per the statistics of WHO, every year 6 mn deaths occur on account of tobacco consumption and around 600,000 people are being exposed to passive smoking and thus suffering from asthma. All these factors are boosting the market for pulmonary drugs. Rise in the investments for research and development to come up with effective drugs is also favoring the growth of this market. Developing nations have a large population base whose needs are unmet, and this is expected to provide a huge opportunity for players in the years to come.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving pulmonary drugs market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16751
Patent Expiration to Hit Pulmonary Drugs Market Hard
The growth of this market is expected to be severely challenged by the patent expiration of important drugs in the coming years. This will obviously impact the market negatively and lead to a decline in the growth of the market. “Emergence of various generic drugs will also threaten the growth of the pulmonary drugs market in the coming years,” says a TMR analyst. Moreover, the strict regulatory process for drug approval will slow down and restrict the growth of this market further. To add to it the availability of counterfeit drugs will hamper the growth of the market.
This review is based on Transparency Market Research’s report, titled “Pulmonary Drugs Market (Drug Class - Inhaled Corticosteroids (ICS), Long-Acting Beta2-Agonists (LABA), Antihistamines, Vasodilators, Short-Acting Beta2-Agonists (SABA), Anticholinergics, Combination Drugs, MAbs, Enzymes, Antibiotics, and Antileukotrienes; Application - Asthma & COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, and Cystic Fibrosis; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, and E-commerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.”

Tissue Banking Market to 2024: Trends, Business Strategies and Opportunities

The global tissue banking market features a large number of highly competitive market players, accentuating the fragmented nature of the competitive landscape, notes Transparency Market Research (TMR). Entry for the new and smaller vendors is expected to be difficult, thanks to the necessity for a vast investments in the domain. The major companies including Taylor-Wharton, Backman Coulter Inc., Thermo Fisher Scientific, Panasonic Biomedical, and Brooks Automation have been engaged in business strategies such as acquisitions and mergers.
A number of companies have been attempting to offer innovative products. For instance, in May 2017, Natera, Inc., a pioneering genetic testing company, announced the launch of a new offering for cord blood stem cells. Evercord, the new service is designed to enable expecting parents in the collection, storing, and potentially retrieving their newborn baby’s cord tissue and blood for therapeutic use in regenerative medicine and transplantation. The project has been undertaken in partnership with one of the most reputable umbilical cord blood banks in the U.S., Bloodworks Nothwest.
This 170 page report gives readers a comprehensive overview of the tissue banking market. Browse through 24 data tables and 66 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/tissue-banking-market.html
The global market for tissue banking is expected to reach a revenue worth US$2.1 bn by 2024, expanding steadily at a CAGR of 11.3% between 2016 and 2024.
Augmenting Incidence of Diseases in North America Spawns Growth
By geography, North America surfaced as the dominant market in the global tissue banking market in 2015. The rising prevalence of cardiovascular diseases, diabetes, and cancer have been boosting the demand for tissue banking across this region. The tissue banking market in Asia Pacific is expected to yield considerable profit over the forthcoming period. By equipment, freezers accounted for the largest share in the global tissue banking market in the same year, driven by the augmenting demand for regenerative medicine, organ transplants, cellular therapies, and blood transfusions.
Escalating Popularity of Regenerative Medicine Assists Expansion
The demand for regenerative medicine has been expanding at a significant pace, owing to the capability of this solution of creating living, functional tissues which are used in the replacement or repairing of tissues lost due to disease, age, congenital defects, or physical damage. This trend is primarily being propelled by an alarming increase in the incidence of neurological and cardiovascular disorders, apart from diabetes and cancer.
Furthermore, the rapid advancement of transplant medicine as well as the unfulfilled medical needs of the aged baby boomer generation have also been fuelling the demand for organs and tissues, contributing toward the expansion of the global tissue banking market. Studies reveal that more than 500,000 people in the U.S. opt for a transplant each year. This number is likely to go up further, aiding the growth of the global market for tissue banking.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving tissue banking market during 2016 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14681
On the downside, the market might face some key bottlenecks due to the lack of adequate infrastructure for storing, freezing, labeling, coding, and monitoring of tissue banks in several regions. Apart from this, the strict regulations applicable to tissue banking, tedious product approval procedures, and incapability of several existing systems of keeping necessary historical records are some other restraining forces of the market for tissue banking. However, the development of innovative products and services is expected to create substantial growth opportunities.
The information presented in this review is based on a Transparency Market Research report, titled, “Tissue Banking Market - (Equipment Type - Freezers, Storage system, Thawing Equipment, Labelling and Coding Equipment, and Alarming and Coding equipment; Application - Clinical and Therapeutic, Research and Development, and Drug Discovery; End users - Hospitals, Tissue Banks, Research and Academics Institutes and Diagnostic Laboratories) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2014 - 2024”.

Interventional Radiology Market - Latest Innovations, Drivers, Restraints, Challenges and Forecast 2016 - 2024

With reference to competition, the global interventional radiology market is highly consolidated, notes Transparency Market Research (TMR). The competitive scenario features GE Healthcare, Hitachi Medical Corporation, Siemens Healthcare, Philips Healthcare, and Toshiba Medical Systems Corporation at the top. In 2015, these five companies held a whopping 60% in the global market for interventional radiology. Product innovation, partnerships, collaborations, mergers, and acquisitions are some frequently adopted business strategies of these firms. Several other firms have been focusing on expanding their presence.
For instance, in May 2017, Alliance Healthcare Services, Inc., a major supplier of outsourced oncology, radiology, and interventional services made an announcement that its oncology division, Alliance Oncology, is partnering Red Rocks Radiation and Oncology, LLC. The primary objective of the partnership is to offer superior clinical quality along with higher patient experience, covering patients residing in the Colorado region.
This 172 page report gives readers a comprehensive overview of the interventional radiology market. Browse through 24 data tables and 60 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/interventional-radiology-market.html
In 2015, the global market for interventional radiology was pegged at US$13.8 bn. Promising significant growth, the market is expected to attain a revenue worth US$22.9 bn by the end of 2024. The global interventional radiology market is expected to expand a healthy CAGR of 5.8% between the forecast years 2016 and 2024.
Growing Incidence of Traumatic Disorders Places Embolization Segment at the Fore
By application, the embolization segment accounted for a share of 24% in 2014 and is expected to continue to hold its dominance over the forecast period as well. The increasing prevalence of diseases such as traumatic injuries has been promoting the advancement of this segment. By geography, North America surfaced as the leading segment of the global interventional radiology market in 2015, thanks to the rising demand for minimally invasive procedures and continuous upgrading of medical devices in the region.
Increasing Geriatric Population Responsible for Growing Demand
One of the primary growth drivers of the global market for interventional radiology is the alarming incidence of obesity all over the globe. Unhealthy eating habits, lack of exercise, and faulty lifestyles are leading to chronic diseases including cardiac conditions. As the number of people suffering from such disorders and diseases increases, the demand for interventional radiology is likely to pick up subsequently.
The rising geriatric population is also propelling the market for interventional radiology. Age is a significant risk factor associated with the contraction of numerous diseases. A great portion of the aging population has already been diagnosed with neurological, cardiovascular, and orthopedic disorders. Despite the advancement of the market, the lack of reimbursement policies across a number of regions can restrict growth. For instance, in developing countries such as India and Brazil, where the reimbursements are already low, a further reduction in reimbursements has been made. The high costs of equipment and surgeries has been responsible for this reduction in reimbursements.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving interventional radiology market during 2016 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1337
Additionally, levying of high excise duties can also pose a challenge to the expansion of the global intervention radiology market. The medical device manufacturers globally are witnessing reduced profit margins, due to the presence of such taxes. However, the global intervention radiology market is likely to pick up steam with the emergence of new techniques used in intervention radiology such as fractional flow reserve and optical coherence tomography.



The information presented in this review is based on a Transparency Market Research report, titled, “Interventional Radiology Market (Products - X-ray, Computed Tomography, Magnetic Resonance Imaging (MRI), and Ultrasound; Application - Angiography, Balloon Angioplasty, Embolization, Biopsy, Vertebroplasty, Kyphoplasty, and RF Ablation; End user - Hospitals, Catheterization Labs, and Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024.”

Medical Aesthetic Devices Market - Latest Innovations, Drivers, Restraints, Challenges and Forecast 2016 – 2024

The global medical aesthetic devices market is extremely competitive and consolidated in nature, wherein a few players account for a key share of the overall market, states a research study by Transparency Market Research. In 2015, the leading players in the market, namely Allergan Plc. and Mentor Worldwide LLC accounted for a share of 60% of the global market. These two players are estimated to remain in the leading position throughout the forecast period. The emergence of new and effective products is one of the key factors estimated to benefit the players in attracting a large number of consumers across the globe. In addition, the increasing number of collaborations in order to enhance the market presence is likely to accelerate the growth of the overall market in the next few years.
As per the research study by Transparency Market Research, in 2015, the global market for medical aesthetic devices was worth US$6.5 bn. The market is likely to reach a value of US$15.1 bn by the end of 2024, exhibiting a progressive 9.0% CAGR between 2016 and 2024.
This 208 page report gives readers a comprehensive overview of the medical aesthetic devices market. Browse through 48 data tables and 81 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/medical-aesthetics.html
North America to Witness Healthy Growth with Rising Geriatric Population
From a geographical perspective, the North America market for medical aesthetic devices is expected witness a substantial growth and count for a key share of the global market. The presence of prominent players in this region is expected to encourage the growth of the market in the next few years. The rising emphasis on research and development activities and the rising geriatric population are anticipated to bolster North America medical aesthetic devices market in the coming years. Furthermore, Latin America and Asia Pacific are projected to offer lucrative opportunities for key players operating in the market. The increasing number of players focusing on emerging nations worldwide is likely to accelerate the growth of the market in the near future.
Among the key product types, the aesthetic laser and energy devices segment is expected to lead the global medical aesthetic devices market in the next few years. The rising preference of dermatologists for these devices is considered as one of the major factors that is estimated to fuel the growth of this segment in the forecast period. In addition, the increasing use of aesthetic laser and energy devices in several applications, especially in skin and hair treatments is expected to accelerate its growth in the next few years.
Rising Demand for Minimally Invasive Surgeries to Encourage Growth
The rising preference of consumers towards aesthetic procedures due to its significant reductions in social taboos and cultural prohibitions is expected to encourage the growth of the global medical aesthetic devices market in the coming years. Moreover, a substantial rise in surgical procedures in order to enhance personal appearance is predicted to generate promising opportunities for key players in the market. Furthermore, the rising demand for minimally invasive surgeries and the rising focus on technological developments are anticipated to supplement the market’s growth in the near future.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving medical aesthetic devices market during 2016 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1039
On the flip side, the global market for medical aesthetic devices is projected to face several growth barriers, owing to the high cost of these devices, especially in emerging nations. However, the rising need to reduce the cost of products in order to stay in the competition the local manufacturers are projected to offer cost-effective and innovative products. This is estimated to encourage the growth of the market in the next few years. In addition, the rising focus on developments is estimated to contribute extensively towards the market’s growth in the coming years.
This information is based on the findings of a research report published by Transparency Market Research (TMR), titled “Medical Aesthetic Devices Market (Product - Aesthetic Laser and Energy Devices, Skin Tightening and Body Contouring Devices, Aesthetic Implants, and Facial Aesthetic Devices; Application - Facial and Body Contouring, Facial and Skin Rejuvenation, Breast Enhancement, Scar Treatment, Reconstructive Surgery, Tattoo Removal, and Hair Removal) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Anti-snoring Devices and Snoring Surgery Market: Challenges and Opportunities

The global anti-snoring devices and snoring surgery market procedures is largely consolidated. In 2014, GE Healthcare, Philips Healthcare, and Medtronic Plc. were the leading players in the market. They had collectively held a share of 93.69% in terms of value. Each of the key players possess exceptionally strong distribution chains and a wide product array under their belts.
According to a new research report released by Transparency Market Research, the threat exuded by new entrants to the global anti-snoring devices and snoring surgery market is expected to remain moderate in the years to come. Key players hold a monopoly over the market through high rates of mergers and acquisitions, while new players are also deterred by high development costs and high costs of surgery.
The global market for anti-snoring devices is expected to be evaluated at US$22.70 bn by 2024. It is projected at a CAGR of 3.9% from 2016 to 2024 and is expected to reach US$16.70 bn by the end of 2016. The global market for snoring surgery procedures is expected to expand at a CAGR of 3.3% from 2016 to 2024. This market’s revenue is expected to reach US$370.95 mn by the end of 2016 and US$481.35 mn by the end of 2024.
This 172 page report gives readers a comprehensive overview of the anti-snoring devices and snoring surgery market. Browse through 73 data tables and 5 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/antisnoring-devices-and-snoring-surgery-market.html
Continuous positive airway pressure devices are expected to continue being the leading anti-snoring device in terms of revenue for the near future. By 2024, this device segment is expected to generate a revenue of US$16.47 bn. Meanwhile, owing to high demand, tongue stabilizing devices are expected to show the leading CAGR of 5.14% from 2016 to 2024.
North America to Continue Leading Anti-snoring Devices and Snoring Surgery Procedures Consumption
North America has consistently generate the leading demand volume for anti-snoring devices and snoring surgery procedures. By the end of 2024, North America is expected to generate US$11.15 bn in revenue from this market. This region has consistently received a timely upgrade of technologies in this field, coupled with a high demand from a large volume of people who are aware of the options.
On the other hand, Asia Pacific is taking the lead in terms of growth in demand by expanding at a projected CAGR 5.2% in revenue from 2016 to 2024. The growth rate is attributed to the significant rate of increase in awareness along with the rising disposable incomes of people.
Growing Sleep Deprivation and Sleep Apnea Cases Propel use of Anti-snoring Devices and Surgery
“Sleep deprivation is a huge problem the people of today’s world are facing. A large number of people are suffering from it and are consequently susceptible to falling prey to chronic diseases, including obesity, hypertension, depression, and diabetes. This forms the core of all reasons driving the need for anti-snoring devices and snoring surgery procedures,” states a TMR analyst.
Sleep apnea is affecting a regularly increasing number of people around the world. Studies conducted by organizations such as the ESADA have already pointed to the incremental growth rate of sleep apnea cases. These patients are high-priority recipients of anti-snoring devices and snoring surgery procedures.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving anti-snoring devices and snoring surgery market during 2016 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6910
Patient Compliance Still Low in Snoring Diagnostics, Hampers Anti-Snoring Device Sales
As stated in earlier research studies, close to a staggering 80% of the patients that were recommended for the usage of CPAP devices were non-compliant to the treatment, citing complaints made of the treatments being too uncomfortable or the devices being too difficult to handle. Most of the patients have shown compliance in the early stages of treatment, but the number of compliant patients dwindles over time due to these issues along with common side-effects such as throat dryness, nasal congestion, or nasal passage dryness.
“Research and development efforts do need to be stepped up, as they already have been by several key players. Examples in recent innovations in this market include the Provent’s release of light, small and battery-operated CPAP devices that can be controlled using Bluetooth communication,” adds the analyst.
The information presented in this review is based on a Transparency Market Research report, titled, “Anti-snoring Devices and Snoring Surgery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Regulatory Affairs Outsourcing Market - Latest Innovations, Drivers, Restraints, Challenges and Forecast 2015 - 2023

Due to the highly fragmented nature of the global regulatory affairs outsourcing market, only a handful of large players have been able to gain significant share in this market over the past couple of years, says a new report by Transparency Market Research (TMR). This, however, has intensified the competitive rivalry in the market with players contending to deliver top-notch services. The top seven players in the market including Quintiles Transnational Holdings Inc., ICON plc, Pharmaceutical Product Development LLC, and PAREXEL International Corporation collectively held a share of 55% in the global market in 2014. The presence of a large number of small and medium-sized companies in the market has been advantageous to the bargaining power of clients.
The scenario demands regulatory affairs outsourcing service providers to top in terms of timeliness and quality. With increasing acceptance of electronics submissions from health governing bodies and compliance agencies, technological advancements will favor regulatory affairs outsourcing service providers to gain competitive edge, says the TMR report.
This 76 page report gives readers a comprehensive overview of the regulatory affairs outsourcing market. Browse through 10 data tables and 18 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/global-regulatory-affairs-outsourcing-market.html
The global market for regulatory affairs outsourcing was worth US$1.9 bn in 2014 and is projected to rise at a CAGR of 11.5% between 2015 and 2023. As such, the market will reach a valuation of US$5.7 bn by 2023.
Cost-effective Outsource Activities Befit over In-house Regulatory Maintenance
With the medical industry witnessing an increased rate of product innovations from companies vying to make a mark in the highly competitive market, investments on research and development are on the rise. In this regard, cost pressures and intense competition are pushing companies to discover new ways to contain costs incurred at the time of regulatory operations and practices principal to the life sciences industry. Outsourcing is increasingly being preferred over in-house data management as it is considered to be cost-effective and resource-efficient way of managing vast amounts of data generated during clinical trials, approvals, and patent approvals.
Moreover, strict regulatory framework in place that governs every facet of development and marketing of medical drugs and device mandate that regulatory documents to be in sync with pre-defined writing guidelines. This is further boosting the need for professional service providers that specialize in data handling related to regulatory affairs thereby further augmenting the need of dependable service providers for regulatory affairs outsourcing.
Varied Regulations Encourages Global Companies to Seek On-the-ground Expertise Help
With life sciences companies continually striving to spread their wings across the globe, the challenges of keeping up with varied and constantly changing regional, local, and national regulations can be overwhelming without expert help. In this scenario, outsourcing regulatory affairs to service providers that have a successful global footprint will be most suitable.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving regulatory affairs outsourcing market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3528
On a regional consideration, regulatory affairs service providers in the emerging economies of Asia Pacific and Latin America are expected to account for the leading number of outsourcing projects worldwide. An increasing number of biopharmaceutical companies are taking off from emerging economies to venture into large markets of North America and Europe.
Product improvement and setting up research and commercialization units is the focus of emerging economies due to cheap resources and cheap cost of raw materials. The large population of Asia Pacific makes for a lucrative regional market for the medical industry. These factors are benefitting the regulatory affairs outsourcing markets in these regions and will help them gain a strong foothold in the next few years.



The review presented is based on the findings of Transparency Market Research report, titled “Regulatory Affairs Outsourcing Market (Services – Regulatory Submissions, Clinical Trial Applications and Product Registrations, Regulatory Writing and Publishing, Regulatory Consulting and Legal Representation) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”

Nanotechnology Drug Delivery Market 2015 - Industry Perspective and Comprehensive Analysis 2023

In 2014, the three leading players in the global nanotechnology drug delivery market - Amgen, Inc., Teva Pharmaceuticals, and Novartis - had held a collective share of 26.3%. This extremely fragmented market comprises of a large number of players that are already globally prominent while still having close to half its size dedicated to regional and local players.
As per the findings revealed by Transparency Market Research in its report, the degree of competition in the global nanotechnology drug delivery market is extremely high, owing to the large number of existing players in it. The demand for nanotechnology drug delivery systems is exceptionally high and is increasing at a fast pace. Additionally, the scope of invention and innovation is still very high, allowing players to find success in even niche roles.
This 120 page report gives readers a comprehensive overview of the nanotechnology drug delivery market. Browse through 12 data tables and 45 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/nanotechnology-drug-delivery.html
The global market for nanotechnology drug delivery is expected to continue its bold CAGR of 12.5% within a forecast period from 2015 to 2023, in terms of revenue. This revenue is expected to reach US$51,969.7 mn by the end of 2016 and US$118,527.2 mn by the end of 2023. In terms of technologies, the global nanotechnology drug delivery market has been dominated by the segment of nanoparticles. By the end of 2023, the applications of nanoparticles in drug delivery are expected to generate US$33,543.2 mn in revenue.
North America Retains Dominant Usage and Scope of Drug Delivery Methods
North America has consistently held the leading spot in the global nanotechnology drug delivery market in terms of value. By the end of 2023, North America is expected to hold 44,450.5 mn of the revenue generated in the global nanotechnology drug delivery market. The primary reason for this is the medical and healthcare advancements that this region had already possessed over others. Close to 80% of all research and development efforts in the global biopharmaceutical industry take place within the U.S., which is also the leading regional user of nanotechnology in healthcare and specifically, drug delivery.
On the other hand, the emerging Asia Pacific region and its booming healthcare sector has put forth its stronger foot. Key countries in this region are exhibiting a phenomenal rate of growth in the healthcare and medical devices industries. This rapid economic growth rate, coupled with a growing expenditure on healthcare by patients, and the steadily increasing demand for the treatment of chronic diseases, is what may set Asia Pacific on track to challenge the greater shares held by North America and Europe.
Nanotechnology Drug Delivery Finds Application Scope Against Multiple Diseases
“The global nanotechnology drug delivery market has one highly sought-after concept working in its favor: the efficacy with which drug delivery can be achieve using these techniques has allowed for the development of incredibly potent drugs that can be used to combat a lot of the top priority diseases of today. The list includes a number of infectious diseases, genetic disorders, pulmonary diseases, cardiovascular diseases, and several forms of cancer,” states a TMR analyst.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving nanotechnology drug delivery market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1822
The introduction of nanotechnology drug delivery has revolutionized the pharmaceutical industry on a much larger scale. The traditional pharmaceutical design of LADME has now been transformed to include other processes such as circulation time, targeting, and triggered activation.
Venture Funds Scarcity Slows Nanotechnology Drug Delivery Market Down
There are quite a few factors responsible for restraining the growth rate of the global nanotechnology drug delivery market. One of the key restraints is the relative lack of venture funds. There are significant investments being made into the market for research and development efforts. However, in the broader picture, the market is still in a very early and formative stage and is in need of deeper investment pools to progress at a satisfactory rate. Other problems include the long waiting time of approval processes and the general lack of accuracy regarding what fields are a part of nano-medicine.
The information presented in this review is based on a Transparency Market Research report, titled, “Nanotechnology Drug Delivery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.”

Multiplexed Diagnostics Market will grows at a CAGR of 20% with increasing prevalence of cancer and infectious diseases

The global multiplexed diagnostics market is highly competitive and dominated by the three players accounting for a combined share of 59.5% in 2015. These top companies are: Thermo Fisher Scientific, Abbott Laboratories, and Agilent Technologies. Transparency Market Research finds that the leading players are constantly offering a diverse product portfolio, investing in acquiring advanced technologies, and expanding their regional presence to gain a competitive edge over others.
The market is otherwise fragmented with the presence of numerous small and mid-sized enterprises holding minor shares. Acquiring high-performing patented technologies, strengthening of distribution network, and intensifying manufacturing activities require substantial investment. This results in a high degree of competition, which poses significant entry barriers for new players. In order to consolidate their presence across regions, the large players are actively resorting to partnerships, mergers, and acquisitions.
This 194 page report gives readers a comprehensive overview of the multiplexed diagnostics market. Browse through 24 data tables and 75 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/multiplexed-diagnostics-market.html
According to TMR’s estimation, the valuation of the global market for multiplexed diagnostics exceeded US$6.0 bn at the end of 2016. From 2016 to 2024, the market is anticipated to exhibit a consistent growth to attain US$26.36 bn by 2024; the global market, when measured in terms of revenue, is expected to expand at a 20.3% CAGR over the forecast period.
Innovative Multiplex Diagnostic Platform to Transform Cardiovascular Care
Geographically, the global multiplexed diagnostics market is segmented into Asia Pacific, North America, Latin America, the Middle East & Africa, and Europe. North America occupied a major market share in 2015. The regional market is anticipated to lead the market along the forecast period. The impressive growth is attributed to a wide prevalence of cardiovascular diseases, rising incidence of cancer in the U.S., and increasing geriatric population. The rapidly evolving healthcare services and innovations in healthcare IT in the U.S. have created ample opportunities for several players, which is expected to propel the regional market. Coupled with this, an enlarged scope of various reimbursements from both public as well as private players is expected to trigger the market growth.
On the basis of application, the multiplexed diagnostics market is segmented into cardiac diseases, oncology, autoimmune diseases, allergies, and infectious disease diagnostic. Of these, cardiac diseases, oncology, and infectious disease diagnostics are prominent market segments providing lucrative opportunities for numerous players to capitalize on. The cardiac disease diagnostics market is anticipated to grow at the highest rate due to wide prevalence of cardiovascular diseases, coupled with the design of high-throughput multiplex diagnostic equipment.
Automation in Multiplex PCR Systems Opens Promising Avenues for Disease Diagnosis
The global multiplexed diagnostics market is primarily driven by the soaring R&D investments by public as well as private players in the areas of genomics and personalized therapies. Constant advances in multiplex diagnostic technology have led to the application of targeted assay for detecting various pathogens for a wide spectrum of chronic and life-threatening diseases, such as neurological and cardiovascular disorders. Multiplexed real-time polymerase chain reaction (PCR) assays, as precision-based diagnostics, enable the concurrent detection of specific pathogens in a single experiment. Automation in multiplex PCR assay has resulted in reduced hands-on-time and elimination of error with high sensitivity and specificity. Along with this, the application of real-time automated multiplex PCR kits helps in rapid detection and significant cost-savings for laboratories, boosting its demand across a large number of diagnostic facilities.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving multiplexed diagnostics market during 2016 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1719
However, the high cost of multiplexed diagnostics assay equipment, combined with lack of operational expertise, is likely to impede the growth of the global multiplexed diagnostics market. Nevertheless, continuous automation in assay technology and application of high-throughput multiplexed PCRs for the detection of a wide range of pathogens are expected to open up exciting opportunities for the leading players.



The study presented here is based on a report by Transparency Market Research (TMR) titled “Multiplexed Diagnostics Market (Technology - Very High Density, High Density, Medium Density, Low Density, and Next Generation Sequencing Assays; Application - Infectious Disease Diagnostics, Oncology, Autoimmune Diseases, Cardiac Diseases, Allergies, and Pregnancy & Fertility Testing; End Use - Academic Research Institutes, Hospitals, Pharmaceuticals Companies, Clinical Research Organizations, and Diagnostic Laboratories) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Active Pharmaceutical Ingredient Industry is Anticipated to Show the Robust Growth During 2015 - 2023

The leading companies operating in the active pharmaceutical ingredients (API) market are Zhejiang NHU Co., Ltd., Teva Pharmaceutical Industries Ltd., Zhejiang Medicine Co., Ltd., Northeast Pharmaceutical Group Co., Ltd., and North China Pharmaceutical Group Corp. and they accounted for the major combined share in 2015. Transparency Market Research (TMR) observes that the top players are opting for strategic mergers and acquisitions to consolidate their shares. The presence of significant barriers to exit and high fixed costs incurred by companies have intensified the competitive landscape in the market.
In order to cut down manufacturing costs, a growing number of pharmaceutical companies, especially in Europe and North America, prefer to outsource manufacturing overseas. These companies which previously had manufacturing units in their home countries are increasingly shifting to regions with cheap availability of labor and raw materials. However, these APIs are subject to stringent regulations of the countries where the pharmaceutical companies are housed. In addition, several players are focusing on research and development activities to develop innovative formulations, notes TMR. The opportunity in the global active pharmaceutical ingredient market stood at US$134.70 bn in 2015. Rising at a CAGR of 6.3% from 2015 to 2023, the market is expected to reach a valuation of US$219.60 bn by the end of 2023.
This 115 page report gives readers a comprehensive overview of the Active Pharmaceutical Ingredient Market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html
Asia Pacific Offers Lucrative Growth Avenues to API Manufacturers
Geographically, North America is the leading market as it accounted for a major share in the global market in 2015. The dominance of this regional market is attributed to the large presence of pharmaceutical companies which require premium quality of APIs. However, in the coming years, Asia Pacific is fast emerging as the major hub for API sourcing driven by cost reduction in manufacturing.
Based on therapeutic areas, the cardiovascular disorders segment dominates the market and is projected to expand at a CAGR of 6.63% from 2015 to 2023. The growing prevalence of various cardiac conditions with complicated etiology is expected to boost the active pharmaceutical ingredient market through the forecast period. A number of blockbuster drugs going off-patents is further expected to stimulate the demand for APIs.
Growing Prevalence of Chronic Conditions to Fuel Market
The active pharmaceutical ingredient market is majorly driven by the growing prevalence of a variety of chronic conditions such as cancer, cardiovascular disorders, metabolic disorders, and neurological disorders. Increasing incidence of these diseases has propelled the demand for therapeutics and novel therapies. This has spurred research in drug formulation for more efficacious treatments. In addition, the rapidly growing geriatric population, especially in developed regions of North America and Europe, is expected to stimulate the demand for APIs in making therapies for various ailments.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving Active Pharmaceutical Ingredient Market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1690
Improving access to quality healthcare in developing regions such as Asia Pacific has propelled the demand for APIs in these regions. In addition, investment by API manufacturers in Asia to adhere to the regulatory compliance requirements, coupled with the tightening regulations by the U.S. FDA on the efficacy of APIs, is expected to boost the global market. However, the growing popularity of generic drugs in developing and resource-poor nations is expected to affect the profit margins of API manufacturers. Nevertheless, various regulatory agencies are working actively to address these concerns, which is expected to unlock exciting opportunities for market players. Substantial spending by various pharmaceutical companies to bolster capacity of API production are also likely to create new opportunities in the market.
The study presented here is based on a report by Transparency Market Research (TMR) titled “Active Pharmaceutical Ingredients (API) Market (Manufacturing Process - Captive Manufacturing and Contract Manufacturing; API Type - Synthetic Chemical API and Biological API; Drug Type - Branded Prescription Drugs, Generic Prescription Drugs, and OTC Prescription Drugs; Therapeutic Area - Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Oncology, Musculoskeletal Disorders, and NSAIDs) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”

U.S. Population Health Management Solutions Market - Latest Innovations, Drivers, Restraints, Challenges and Forecast 2015 - 2023

With the continual entry of new players, the U.S. population health management solutions market is likely to witness intense competition in the years to come. The deepening rivalry between leading vendors of population health management solutions in the U.S., namely, Wellcentive, IBM, The Advisory Board Co., and McKesson, is expected to add considerably to this scenario over the next few years.
As per TMR, the U.S. market for population health management solutions held an opportunity worth US$3.4 bn in 2014. Expanding at an impressive CAGR of 23.90% over the forecast period of 2015 to 2023, the market is likely to increase to US$45.7 bn by the end of the forecast period. Although software will continue to be the main source of population health management solutions in the U.S. throughout the forecast period, the demand for services will rise at a higher CAGR of 30.30% between 2015 and 2023.
This 93 page report gives readers a comprehensive overview of the U.S. population health management market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/us-population-health-management-solutions-market.html
Demand for Web-based Population Health Management Solutions to Remain High
Apart from the source, the report also classifies the U.S. market for population health management solutions on the basis of the mode of operation and end user. Based on the mode of operation, the market has been categorized into web-based solutions, premise-based solutions, and cloud-based solutions. Among the three, the demand for web-based population health management solutions is greater, thanks to the increased penetration of internet across the U.S. The scenario is expected to remain so with the revenue by this segment crossing US$23.2 bn by the end of 2023.
Private insurance providers, government insurance providers, healthcare providers, medical device organizations, pharmaceuticals companies, and others, including employers, research institutes, and diagnostic and imaging centers, have emerged as the key end users of population health management solutions in this country. Healthcare providers have been registering the most prominent demand for these solutions and are expected to continue this trend over the next few years, states the research report.
Implementation of U.S. Affordable Care Act to Influence Demand for Population Health Management Solutions
“The demand for population health management solutions in the U.S. has been heavily influenced by the implementation of the U.S. Affordable Care Act (ACA),” states a researcher at TMR. As the act excludes payments for unnecessary readmissions, making hospitals financially accountable for patients up to thirty days after their discharge, it is expected to play an important role in the expansion of these solutions over the next few years in this country. Besides, the increasing base of the U.S. geriatric population and the rising incidence of chronic diseases are also projected to fuel the demand for population health management solutions here substantially in the near future.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving U.S. population health management market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7412
On the other hand, the need for heavy investments for the development of a proper infrastructure is likely to limit the growth of this market to some extent in the coming years. The dearth of skilled professionals will also impact the market negatively, reports the research study.
The study presented here is based on a report by Transparency Market Research (TMR) titled “U.S. Population Health Management Solutions Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015–2023.”
The U.S. population health management solutions market is segmented into:
By Source

• Software
• Service

By Mode of Operation

• Premise-based Population Health Management Solutions
• Cloud-based Population Health Management Solutions
• Web-based Population Health Management Solutions

By End User

• Health Care Providers
• Government Insurance Providers
• Private Insurance Providers
• Pharmaceuticals Companies
• Medical Device Organizations
• Others (employers, diagnostic and imaging centers, and research institutes)